There are 594 resources available
72P - Optimizing treatment strategies for EGFR 21L858R mutation non-small cell lung cancer with brain metastases: A real-world analysis of first-line EGFR-TKI efficacy
Presenter: Likun Chen
Session: Poster Display session
73P - Real-world post-progression analysis of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display session
74P - First-line treatment in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC): A review and individual patient data (IPD) comparison of phase III clinical trials
Presenter: Andrea Torchia
Session: Poster Display session
75P - Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R mutated non-small cell lung cancer
Presenter: Zhou Jin
Session: Poster Display session
76P - Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
Presenter: Frank Griesinger
Session: Poster Display session
77P - EGFR-mutant advanced NSCLC patients continuously benefit from aumolertinib as post secone-line treatment
Presenter: zhihua liu
Session: Poster Display session
78P - Balancing Efficacy and Safety: Systematic Review of Osimertinib Plus Chemotherapy in advanced EGFR-Mutated NSCLC
Presenter: Omar Daas
Session: Poster Display session
79P - Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
Presenter: Victor Moreno Garcia
Session: Poster Display session
80P - Final overall survival and long-term safety outcomes of savolitinib in patients with locally advanced or metastatic NSCLC harboring METexon 14 (METex14) mutation: An update from a phase IIIb study
Presenter: Yongfeng Yu
Session: Poster Display session
81P - Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
Presenter: Julien Mazieres
Session: Poster Display session